78 related articles for article (PubMed ID: 32627420)
1. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Burmester G; Drescher E; Hrycaj P; Chien D; Pan Z; Cohen S
Clin Rheumatol; 2020 Nov; 39(11):3341-3352. PubMed ID: 32876780
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
4. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.
Kaur P; Chow V; Zhang N; Moxness M; Kaliyaperumal A; Markus R
Ann Rheum Dis; 2017 Mar; 76(3):526-533. PubMed ID: 27466231
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH; Smolen JS
Ann Rheum Dis; 2017 Jan; 76(1):58-64. PubMed ID: 26318384
[TBL] [Abstract][Full Text] [Related]
8. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
[TBL] [Abstract][Full Text] [Related]
9. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin
Demarchi M; Coliat P; Mclendon K; Chung Shii Hii J; Feyaerts P; Ang F; Jaison L; Deforce F; Derde MP; Kim MJ; Park LS; Detappe A; Pivot X
Pharmacol Res Perspect; 2021 Aug; 9(4):e00839. PubMed ID: 34309241
[TBL] [Abstract][Full Text] [Related]
10. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
Lee HA; Kim S; Seo H; Kim S
Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study.
Zubrzycka-Sienkiewicz A; Klama K; Ullmann M; Petit-Frere C; Baker P; Monnet J; Illes A
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38316489
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
[TBL] [Abstract][Full Text] [Related]
13. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
Yoo DH; Suh CH; Shim SC; Jeka S; Cons-Molina FF; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kwon TS; Park W
Ann Rheum Dis; 2017 Mar; 76(3):566-570. PubMed ID: 27624791
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg
Roth K; Lehnick D; Wessels H; Höfler J; Gastl B; Jankowsky R
Pharmacol Res Perspect; 2019 Oct; 7(5):e00503. PubMed ID: 31417680
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial.
Wessels H; von Richter O; Velinova M; Höfler J; Chamberlain P; Kromminga A; Lehnick D; Roth K
Expert Opin Biol Ther; 2023; 23(12):1287-1297. PubMed ID: 38044885
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
[TBL] [Abstract][Full Text] [Related]
17. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.
Schoergenhofer C; Schwameis M; Firbas C; Bartko J; Derhaschnig U; Mader RM; Plaßmann RS; Jilma-Stohlawetz P; Desai K; Misra P; Jäger U; Jilma B
Sci Rep; 2018 Jan; 8(1):124. PubMed ID: 29317666
[TBL] [Abstract][Full Text] [Related]
18. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study.
Jeong H; Kang T; Lee J; Im S
Int J Clin Pharmacol Ther; 2024 May; 62(5):231-240. PubMed ID: 38174886
[TBL] [Abstract][Full Text] [Related]
19. Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study.
Zhou W; Wang M; Yu Y; Wang J; Wu Y; Yang G; Yu H; Li J; Zhou L; Zhang Q
Expert Opin Biol Ther; 2023; 23(8):717-725. PubMed ID: 36843059
[TBL] [Abstract][Full Text] [Related]
20. Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product.
Cantin G; Liu Q; Shah B; Kuhns S; Wikström M; Cao S; Liu J
Drugs R D; 2023 Dec; 23(4):421-438. PubMed ID: 37831372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]